Approval · Notice of Compliance 15485 · 2014
ATACAND: Notice of Compliance 15485
Issued April 8, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15485
- Date
- April 8, 2014
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication for pediatric patients
- Therapeutic class
- Angiotensin II at1 receptor blocker
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATACAND | Not yet assigned | — |
Medicinal ingredients
- CANDESARTAN CILEXETIL 4 MG per TAB
- CANDESARTAN CILEXETIL 8 MG per TAB
- CANDESARTAN CILEXETIL 16 MG per TAB
- CANDESARTAN CILEXETIL 32 MG per TAB